The prevalence of diabetes mellitus and abnormal glucose metabolism in the inpatient psychiatric setting:A systematic review and meta-analysis by Roberts, Emmert et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.genhosppsych.2017.01.003
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Roberts, E., Jones, L., Blackman, A., Dewhurst, T., Matcham, F., Kan, C., ... Price, H. (2017). The prevalence of
diabetes mellitus and abnormal glucose metabolism in the inpatient psychiatric setting: A systematic review and
meta-analysis. GENERAL HOSPITAL PSYCHIATRY, 45, 76-84. [76].
https://doi.org/10.1016/j.genhosppsych.2017.01.003
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
The prevalence of diabetes mellitus and abnormal glucose
metabolism in the inpatient psychiatric setting: A systematic
review and meta-analysis
Emmert Roberts, Leah Jones, Alexandra Blackman, Thomas
Dewhurst, Faith Matcham, Carol Kan, Omar Mustafa, Toral
Thomas, Najma Siddiqi, Khalida Ismail, Hermione Price
PII: S0163-8343(16)30210-9
DOI: doi: 10.1016/j.genhosppsych.2017.01.003
Reference: GHP 7172
To appear in: General Hospital Psychiatry
Received date: 5 August 2016
Revised date: 24 December 2016
Accepted date: 8 January 2017
Please cite this article as: Emmert Roberts, Leah Jones, Alexandra Blackman, Thomas
Dewhurst, Faith Matcham, Carol Kan, Omar Mustafa, Toral Thomas, Najma Siddiqi,
Khalida Ismail, Hermione Price , The prevalence of diabetes mellitus and abnormal
glucose metabolism in the inpatient psychiatric setting: A systematic review and meta-
analysis. The address for the corresponding author was captured as affiliation for all
authors. Please check if appropriate. Ghp(2017), doi: 10.1016/
j.genhosppsych.2017.01.003
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 1 
Title: 
The Prevalence of Diabetes Mellitus and Abnormal Glucose Metabolism in the Inpatient 
Psychiatric Setting: A Systematic Review and Meta-Analysis 
 
Author names and affiliations: 
Dr Emmert Roberts (ER) MRCP (UK), Department of Psychological Medicine, Institute of 
Psychiatry, Psychology & Neuroscience, King's College London, UK 
Dr Leah Jones (LJ) MRCPsych (UK), South London and Maudsley NHS Foundation Trust, 
Denmark Hill, London, UK 
Dr Alexandra Blackman (AB) MRCPsych (UK), South London and Maudsley NHS 
Foundation Trust, Denmark Hill, London, UK 
Dr Thomas Dewhurst (TD) MRCPsych (UK), South London and Maudsley NHS 
Foundation Trust, Denmark Hill, London, UK 
Faith Matcham (FM) Department of Psychological Medicine, Institute of Psychiatry, 
Psychology and Neuroscience, King’s College London, UK. 
Dr Carol Kan (CK) MRCP (UK), Department of Psychological Medicine, Institute of 
Psychiatry, Psychology & Neuroscience, King's College London, UK 
Dr Omar Mustafa (OM) MRCP (UK), Department of Diabetes, King’s College Hospital, 
Denmark Hill, London, UK 
Dr Toral Thomas (TT) MRCPsych (UK), The Herschel Prins Centre, Leicester, UK 
Dr Najma Siddiqi (NS) PhD, Health Sciences, University of York, Hull York Medical 
School, York, UK; Bradford District Care NHS Foundation Trust, Bradford, UK 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 2 
Professor Khalida Ismail (KI) Department of Psychological Medicine, Institute of 
Psychiatry, Psychology & Neuroscience, King's College London, UK 
Dr Hermione Price (HP) DPhil, West Hampshire Community Diabetes Service, Southern 
Health NHS Foundation Trust, Pikes Hill, Lyndhurst, UK 
 
Corresponding author: 
Dr Emmert Roberts, Academic Clinical Fellow in Psychiatry, South London and Maudsley 
NHS Foundation Trust, Department of Psychological Medicine, Institute of Psychiatry, 
Psychology & Neuroscience, King's College London, Weston Education Centre, 10 
Cutcombe Rd, London SE5 9RJ 
emmert.roberts@kcl.ac.uk 
+ (44) 7754156145 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 3 
Title: 
The Prevalence of Diabetes Mellitus and Abnormal Glucose Metabolism in the Inpatient 
Psychiatric Setting: A Systematic Review and Meta-Analysis 
 
Running title: 
The prevalence of abnormal glucose metabolism in psychiatric inpatients 
 
Article data: 
Word count (Abstract): 199 
Word count (Text): 2802 
Number of tables: 3  
Number of online supplementary appendices: 2 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 4 
Abstract: 
Objective: To systematically determine the prevalence of diabetes mellitus (DM), 
impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) in psychiatric 
inpatients and explore the impact of patient and study variables on prevalence 
estimates. 
Method: We searched EMBASE, PsychINFO, Medline and CENTRAL from database 
inception until 1st December 2015. We included studies of any design reporting 
prevalence of abnormal glucose metabolism in any adult psychiatric inpatients. We 
conducted a random effects meta-analysis to generate pooled prevalence estimates. Chi-
square tests compared differences within categorical variables (inpatient setting, 
continent of study and patient diagnostic category) and Spearman’s correlation analyses 
assessed the impact of linear variables (age, year of data collection and study quality). 
Study quality was assessed using an adapted Newcastle-Ottawa Scale.  
Results: 36 study reports representing 42 unique cohorts were included. Across all 
studies prevalence of unspecified type DM was 10% (95%CI: 9-12), of T1DM was 1% (0-
1), of T2DM was 9% (6-13), of IFG 18% (8-28), and of IGT was 22% (16-28). These 
estimates were not affected by study quality.  
Conclusions: All estimates are higher compared to the general population. Mental health 
professionals should be aware of this elevated prevalence to improve screening and 
management of abnormal glucose metabolism. 
 
Keywords: 
Diabetes Mellitus, Serious Mental Illness, Inpatient Psychiatry 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 5 
 
Introduction 
The prevalence of diabetes mellitus (DM) and abnormal glucose metabolism is often 
reported as higher in psychiatric inpatients compared to the general population, [1] and 
as a co-morbidity has been associated with an increased length of stay. [2] Psychiatric 
patients with abnormal glucose metabolism have poorer long-term outcomes including 
increased tendency to relapse of mental illness, [3,4] and increased mortality secondary 
to an increased risk of cardiovascular disease. [5] Appropriate detection and treatment 
of abnormal glucose metabolism is thus an important target for interventions to 
improve clinical outcomes in psychiatric inpatients.  Reported prevalence estimates for 
DM in psychiatric inpatients range from 2% to 25% and are often based on small cross-
sectional studies, [6,7] which frequently are limited to subpopulations, including those 
with particular diagnoses or on particular psychotropic medication. [8]  
Previous systematic reviews in patients with psychiatric illness have focused on the 
prevalence of metabolic syndrome, or of exclusively type two diabetes mellitus (T2DM). 
[9, 10, 11, 12, 13] Whilst rates of 30-40% [9,14] of metabolic syndrome, and 7-13% of 
T2DM [12,13] are commonly reported they offer no specific detail on prevalence of 
T1DM or impaired glucose metabolism, and do not focus on the psychiatric inpatient 
setting. The burden of disease of DM, impaired fasting glucose (IFG), and impaired 
glucose tolerance (IGT) within the inpatient setting remains uncertain despite these 
disease states having specific and alternative interventions available as management 
strategies, with the inpatient setting representing an excellent window of opportunity 
for both screening and intervention. Improved knowledge and screening for abnormal 
glucose metabolism has the potential to improve and personalise inpatient psychotropic 
prescribing regimens leading to fewer diabetogenic prescriptions in those with states of 
impaired glucose metabolism but without frank diabetes.  
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As yet no systematic review has provided pooled prevalence estimates of all types of 
DM, IFG or IGT in psychiatric inpatients despite an increase in the awareness of the need 
for physical health screening and management of chronic medical conditions in patients 
with psychiatric illness. [15] With greater emphasis being placed on improving 
diagnosis and management of co-morbid medical conditions within psychiatric inpatient 
settings, this study aims to systematically review the literature and fill this gap. We 
aimed to present a pooled prevalence of DM, IFG and IGT in psychiatric inpatients and to 
explore the impact of study populations and characteristics on prevalence estimates. 
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Methods 
Data sources 
We searched Embase, Medline, PsychINFO and the Cochrane Central Register of 
Controlled Trials, from database inception to December 1st 2015 for studies published in 
English. Three authors (XX, XX and XX) initially assessed the titles and abstracts 
identified by the search and reviewed the full text of the remaining articles for inclusion. 
Any discrepancy was resolved by discussion, and where agreement could not be 
reached a fourth author (ER) was consulted. All relevant references were checked for 
additional citations. The full search terms can be found in the online supplementary 
material eFigure one.  
Study Selection 
We included full studies of adult participants (18-65) in any psychiatric inpatient 
setting. These were subdivided into general adult, intensive care, rehabilitation, learning 
disability, forensic, eating disorder and addiction inpatient units. We included studies of 
any design, any adult psychiatric inpatient with any diagnoses, and which reported a 
prevalence of diabetes mellitus T1 or T2, or IFG or IGT. We excluded those studies which 
were conducted in mixed inpatient and outpatient settings and prevalence estimates 
were unable to be calculated separately for inpatient cohorts, and those studies which 
only reported percentages of prevalence from which we could not calculate the absolute 
number of patients diagnosed with abnormal glucose metabolism. Where multiple 
studies reported on the same patient cohort the more conservative estimate was used 
for meta-analysis. 
Data Extraction 
Three authors (XX, XX and XX) independently extracted diagnostic categories of patients 
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studied; mean patient age, psychiatric diagnoses, year of data collection, the country in 
which the study was conducted and method of diagnostic assessment of abnormal 
glucose metabolism. We planned a priori to group studies into three-year strata from 
the earliest year of collection, into continent on which they were conducted, and into 
four diagnostic categories (any inpatient, schizophrenia or schizoaffective disorder, any 
mood disorder and any substance use disorder) for separate analyses.  
 
Quality assessment   
A 10-point quality assessment tool was adapted from the Newcastle-Ottawa Scale [16] 
(available in the online supplementary material as eFigure two). This scale is used to 
assess the methodological quality of observational studies and has acceptable validity 
and reliability. The scale can be modified and was adapted to take into account the 
adequacy of criteria used to determine the diagnosis of diabetes or impaired glucose 
metabolism. A diagnosis was deemed adequate if it was based on international criteria 
(e.g. the American Diabetes Association criteria [17] or World Health Organization 
(WHO) criteria [18]). Methodological considerations in each study were scored as 
follows: 0-5 points for adequate selection of study subjects, 0-2 points for adequate 
comparability of study subjects and 0-3 points for adequate outcome assessment. 
Overall study quality was scored as follows: 0-3 = low quality; 4-7 = medium quality; 8-
10 = high quality. 
 
Data Synthesis and Statistical Analysis 
Data were pooled according to diagnoses of IFG, IGT or DM; either undefined in 
individual studies or defined as type one (T1DM) or type two (T2DM). We expected 
heterogeneity to be moderately high between studies due to variation in data sampling, 
and therefore planned to conduct a random-effects meta-analyses with 95% Confidence 
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Intervals (CIs). Heterogeneity was assessed using I2, with thresholds of ≥25%, ≥50% and 
≥75% indicating low, moderate and high heterogeneity, respectively [19]. Subgroup 
analyses explored whether prevalence estimates of unspecified DM were influenced by 
type of inpatient setting, continent on which study was performed, year of data 
collection, diagnostic category of participants, and overall study quality. Chi-square tests 
were used to compare differences within categorical variables (setting, continent and 
diagnostic category) and Spearman’s correlation analyses with adjusted ρ2 assessed the 
impact of linear variables (age, year of data collection and study quality) on prevalence 
estimates with the significance level set at 0.05. Where significant differences in 
prevalence of unspecified DM were demonstrated within subgroups heterogeneity was 
explored with meta-regression analyses to investigate potential moderators. We 
planned to conduct sensitivity analyses using only those studies with adequate reported 
criteria to determine the diagnosis of diabetes or impaired glucose metabolism, and 
removing those studies which preselect only patients treated with antipsychotic 
medication. Funnel plots were produced to explore the possibility of publication bias 
due to preferential publication of small studies reporting high prevalence estimates; 
Egger’s test of publication bias was also performed. All analyses were conducted with 
STATA version 12.0. Ethical approval was not required for the study. The study was 
conducted in accordance with the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines, and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [20, 
21]. This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
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Results 
The search identified 1114 abstracts. 100 full texts were examined and 36 study reports 
comprising 42 unique cohorts were included in the analysis. An included studies flow 
diagram and list of excluded studies can be found in the online supplementary material 
as eFigure three and eTable one respectively. Thirty one study cohorts reported the 
prevalence of DM of unspecified type, five reported prevalence of T1DM, thirteen of 
T2DM, seven of IFG and three of IGT. Across all studies prevalence of unspecified type 
DM was found to be 10% (95% CI: 9-12), of T1DM was 1% (0-1), of T2DM was 9% (6-
13), of IFG 18% (8-28) was and of IGT was 22% (16-28).  A description of included 
study characteristics can be found in table one, and the number of study cohorts and 
prevalence for each analysis can be found in table two. Forest plots for each analysis can 
be found in the online supplementary material as eFigure four. 
Setting: 
There were no studies in psychiatric intensive care, eating disorder or learning disabled 
inpatient settings.  31 study cohorts were reported in general adult, 3 in addiction, 4 in 
forensic and 4 in rehabilitation inpatient settings. The prevalence of unspecified type 
diabetes mellitus was found to be 10% (95%CI: 9-12) in general adult, 11% (0-23) in 
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addiction, 10% (6-13) in forensic and 12% (4-21) in rehabilitation inpatient settings. 
The prevalence of unspecified DM did not differ by setting.  
Continent: 
There were no studies conducted in the continents of South America, Africa or 
Australasia. 13 study cohorts were reported in Europe, 17 in Asia and 12 in North 
America. The prevalence of unspecified type diabetes mellitus was found to be 9% (95% 
CI: 7-12) in Europe, 11% (6-16) in Asia, and 11% (9-12) in North America.. The 
prevalence of unspecified DM did not differ by continent. 
Diagnostic Category: 
22 study cohorts reported on any inpatients, 9 on patients with schizophrenia or 
schizoaffective disorder, 8 on patients with any mood disorder and 3 on patients with 
any substance use disorder. The prevalence of unspecified type diabetes mellitus was 
found to be 11% (95% CI: 10-12) in any inpatients, 11% (5-17) in patients with 
schizophrenia or schizoaffective disorder, 8% (4-12) in patients with any mood disorder 
and 11% (0-23) in patients with any substance use disorder. The prevalence of 
unspecified DM did not differ by diagnostic category. 
Mean patient age: 
31 study cohorts reported mean age. The mean age of patients ranged from 33 to 54 
years old. The prevalence of unspecified DM did not differ by mean patient age. 
Year of data collection: 
Studies were grouped into three-year strata from 1997 onwards. Two study cohort’s 
data were collected before 1997, 4 from 1997-1999, 4 from 2000-2002, 8 from 2003-
2005, 7 from 2006-2008, 5 from 2009-2011, and 2 from 2012-2014. 10 did not report 
period of data collection. The prevalence of unspecified type diabetes mellitus was 
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found to be 9% (95% CI 7-12) before 1997, 8% (7-10) from 1997-1999, 11% (10-13) 
from 2000-2002, 13% (11-14) from 2003-2005, 6% (3-9) from 2006-2008, 9% (6-13) 
from 2009-2011, and 12% (2-23) from 2012-2014. Spearman’s correlation analyses 
demonstrated that year of data collection did not show a significant association with 
prevalence estimates of unspecified DM. 
Quality:   
16 study cohorts were rated as low, 12 were rated as medium, and 14 were rated high 
quality. The prevalence of unspecified type diabetes mellitus was found to be 9% (95% 
CI: 6-11) in low quality study cohorts, 12% (8-16) in medium quality study cohorts and 
11% (9-12) in high quality study cohorts. Spearman’s correlation analyses 
demonstrated that study quality did not show a significant association with prevalence 
estimates of unspecified DM. 
Sensitivity Analysis: 
When restricted to those studies reporting adequate criteria to determine the diagnosis 
of diabetes or impaired glucose metabolism there was no significant difference in the 
prevalence estimates of all measures of abnormal glucose metabolism. When those 
studies recruiting only patients treated with antipsychotic medication were removed 
there was no significant difference in the prevalence estimates of all measures of 
abnormal glucose metabolism. 
We found no evidence of publication bias for all measures of abnormal glucose 
metabolism. Funnel plots can be found in the online supplementary material as eFigure 
five.  
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Discussion 
Across all studies one in ten psychiatric inpatients has a diagnosis of diabetes mellitus, 
one in five has a diagnosis of impaired fasting glucose and one in five has a diagnosis of 
impaired glucose tolerance. The prevalence of T2DM is consistent with other reviews in 
patients with serious mental illness (SMI), but to our knowledge we are the first group 
to report a pooled prevalence of impaired glucose metabolism in psychiatric inpatients. 
All estimates are higher compared to the general population [58], and comparable to 
psychiatric patients in outpatient settings. [13, 59] Although studies varied widely in 
terms of quality, subgroup and Spearman’s rank correlation analysis indicate that 
prevalence estimates were reasonably stable.  
There was no consistent pattern that abnormal glucose metabolism had a higher 
prevalence in any specific type of inpatient setting. No clear pattern of significantly 
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differential prevalence was found in terms of diagnostic category, however patients with 
schizophrenia or schizoaffective disorder had higher rates of T2DM and IFG, again a 
consistent finding with other studies. [60] We are unable to comment on the aetiology of 
this increased prevalence though hypothesise it may be linked to antipsychotic 
medication use in these patients. [61,62] We were unable to identify sufficient detail 
from reporting in included studies to stratify analyses by numbers of patients with 
current or past antipsychotic medication use, or patient ethnicity.  
We used rigorous methods to conduct the review, with a broad search and a structured 
approach to data extraction. We took a comprehensive approach into the construct of 
inclusion criteria, including studies of all designs, and subpopulations using subgroup 
analysis to assess the impact of study and population variables as opposed to exclusion 
of such studies from the outset. Prevalence estimates are susceptible to potential 
publication bias based on the assumption that small studies reporting low prevalence of 
abnormal glucose metabolism would be less likely to be published than small studies 
reporting high prevalence. We explored publication bias by visual inspection of funnel 
plots and Egger’s test, which can be found in the online supplementary material as 
eFigure five. We found no evidence of publication bias for all measures of abnormal 
glucose metabolism.  
There are several limitations to the review. The number of studies included is relatively 
small and pooling demonstrates consistently high heterogeneity between prevalence 
estimates for unspecified DM, T2DM, IFG and IGT. Many studies did not report methods 
by which diabetes mellitus was diagnosed, and some relied on use of anti-diabetic 
medication as a proxy measure for diagnosis. As anti-diabetic medication may be 
prescribed for reasons other than frank diabetes this has the potential to overestimate 
the prevalence. However we conducted a sensitivity analysis restricted to only those 
prevalence estimates from cohorts that reported adequate criteria to determine the 
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diagnosis of diabetes or impaired glucose metabolism, and there was no significant 
difference in the prevalence estimates for all measures of abnormal glucose metabolism. 
A further consideration is the representativeness of the sample from which prevalence 
levels are estimates. No studies were conducted in psychiatric intensive care, eating 
disorder and learning disabled settings, or in South America, Africa or Australasia thus 
results cannot be generalised to these settings. There were also a number of excluded 
studies which were conducted in mixed inpatient and outpatient settings and 
prevalences were unable to be calculated separately for inpatient cohorts due either to 
sampling methods or lack of reporting. 
The main reason for identification and clarification of the prevalence of a disease is to 
raise awareness of the scale of the problem and ultimately intervene to improve clinical 
outcome. Given the high numbers of patients with abnormal glucose metabolism, and 
the links to psychotropic drug use as a putative causative and exacerbating factor 
[61,62] there is an argument that psychiatrists and mental health professionals be 
better trained and empowered to detect and manage abnormal glucose metabolism. 
There is often a reticence of ownership of responsibility for managing co-morbid 
medical conditions by psychiatrists, [63] and large variation exists in provision for 
management of co-morbid medical conditions within psychiatric inpatient facilities. [63] 
There has been recognition that abnormal glucose metabolism management strategies 
may be unsuitable or unacceptable to some patients with psychiatric illness due to a 
variety of patient, provider and system factors. [64] Indeed a prevalence of one in five 
for IFG or IGT is higher than estimates for number of inpatients with bipolar affective 
disorder and some personality disorders across all inpatient settings, [65] suggesting 
that abnormal glucose metabolism should be an essential part of psychiatric 
postgraduate examination, training and expertise. [66]  
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Future research should focus on prevalence estimates in settings not currently reported 
on including eating disorders, learning disabled and psychiatric intensive care settings, 
and on translating the knowledge of increased prevalence of these conditions into 
action; emphasising their screening and management in a system that should advocate 
holistic care of the patient.  
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Tables 
Table one: 
 
Included Studies 
NR: Not reported; DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD: International Classification of Diseases; USA: United States of 
America; UK: United Kingdom 
 
Study ID Setting Year/s of Data 
Collection 
Country  Quality 
(0-10) 
Mean 
Age 
 Abnormal Glucose 
Diagnosic Criteria 
Psychiatric 
Diagnostic Criteria 
Unspecified 
DM 
(Cases/Total) 
T1DM T2DM IFG IGT 
Blank 201022 General Adult Apr 2003 - Mar 
2006 
USA 3 NR 
(Range 
35-64) 
NR All inpatients aged 
≥ 35 with a clinical 
diagnosis of Major 
Depressive Disorder 
201/1401 . . . . 
Cassidy 199923 General Adult NR USA 3 42.1 NR DSM III -R criteria 
for bipolar disorder 
manic or mixed 
subtype 
36/345 . . . . 
Citrome 200624 General Adult 1997 - 2004 USA 8 45.7  Received 
prescriptions of 
antidiabetic 
medication or a 
recorded diagnosis 
of diabetes mellitus 
(ICD-9 
250.xx) 
Every inpatient in 
the 
17 adult civil 
facilities of the New 
York State 
psychiatric hospital 
system. 
1997: 
696/10091 
. . . . 
45.1 1998: 794/9424 
44.5 1999: 836/9008 
44.3 2000: 842/8621 
44 2001: 969/8520 
44 2002: 
1068/8269 
44.1 2003: 
1038/7724 
44.2 2004: 
1079/7420 
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Go 200925 General Adult Jan 2006 - Aug 
2007 
Phillipines 8 40 Documented DM 
type II' 
DSM-IV TR criteria 
for schizophrenia 
. . 1/227 . . 
Goethe 200626 General Adult 2003 USA 3 42.4 Diabetes Diagnosed' All inpatients 
treated with 
antipsychotic 
medication 
188/1691 . . . . 
Hennings 201027 General Adult NR Germany 3 44.2 IGT: Glucose > 
140mg/dL 120 mins 
after glucose intake 
Inpatients with 
major depression 
without lifetime 
Axis I diagnosis 
. . . . 4/10 
Kan 201528 General Adult  2013 - 2014 UK 6 50.2 NR Any Inpatient 31/411 2/411 29/411 . . 
Kanzaki 201529 General Adult Jan 2012 - Dec 
2013 
Japan 4 54.3 Diabetes mellitus was 
defined as 
haemoglobin A1c 
(HbA1c) ≥ 6.5% and 
fasting plasma 
glucose ≥ 126 mg/dL 
or use of 
hypoglycaemic agents 
Any Inpatient 28/152 . . . . 
Kelbrick 201330 General Adult Jan 2011 - Jun 
2011 
UK 3 48 DM: NR       IFG: 
Patients without DM 
+ BM >7 mmol/litre 
Any primary 
affective disorder 
according to ICD10 
criteria 
8/70 1/70 7/70 2/70 . 
Kim 200931 General Adult Jan 2005- Dec 
2006 
South Korea 3 38 Anti diabetic 
medication 
DSM-IV Bipolar I 8/184 . . . . 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
 
 28 
Kimijima 201132 General Adult 2007 - 2008 Japan 1 53.5 NR Schizophrenia 
included schizotypal 
and delusional 
disorders (ICD F20-
F29 
. - 24/138 . . 
Levine 200133 General Adult 1998 - 1999 USA 7 40 T2DM: Fasting blood 
glucose > 140 mg/dl 
on two occasions or a 
2 hour postprandial 
blood glucose ≥ 200 
mg/dl; subjects with 
diabetes mellitus had 
already been 
diagnosed and were 
all receiving dietary 
and/or 
pharmacological 
treatment for glucose 
control 
Any inpatient .   30/414 . . 
Lilliker 198034 General Adult Jan 1969 – Dec 
1978 
USA 4 58 NR DSM II Manic-
depressive illness, 
manic type: manic-
depressive illness, 
depressed type; 
manic-depressive 
illness, circular type 
20/203 . . . . 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
 
 29 
Lindenmayer 
200335 
General Adult  NR: Olanzapine 
arm added 1997 
USA 9 40.33 NR DSM-IV crieria for 
schizophrenia or 
schizoaffective 
disorder 
7/108 . . . . 
Luppino 201436 General Adult Jan 2007 - Dec 
2009 
Netherlands 3 44.8 NR Any inpatient with 
DSM IV major 
depressive disorder 
2/80 . . . . 
Manu 201237 General Adult Aug 2010 - Dec 
2010 
USA 8 45.2 NR Any inpatient 121/1000 . . . . 
Manu 2012/1338,39 General Adult Nov 2003 - Jul 
2007 
Belgium 10 37.6 
DM: FPG 
≥125mg/dL or 2 
hour OGTT 
>199mg/dL or 
HbA1c >6,4%     IFG: 
Excludes those with 
DM or ‘IGT’ defined 
as a fasting plasma 
glucose greater than 
125 mg/dL, 2-h 
glucose level during 
OGGT 140 mg/dL or 
greater and 
hemoglobin A1c 
6.5% or greater    
Any inpatient on 
Antipsychotic 
medication 
80/783  . . 91/783  . 
Mookhoek 201140 General Adult NR Netherlands 4 48 DM: used anti-
diabetic medication, 
or had fasting serum 
Any inpatient 39/256 3/256 36/256 36/256 . 
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glucose levels over 
6.9 mmol/l or non-
fasting serum glucose 
levels over 11.0 
mmol/l            
IFG:Used no anti-
diabetic medication 
and had fasting serum 
glucose levels 
between 6.1 and 6.9 
mmol/l or non-fasting 
serum glucose levels 
between 7.0 and 11.0 
mmol/l, 
Ono 201341 General Adult NR Japan 4 40 IFG: A fasting 
glucose level of 100-
125 mg/dL IGT: A 2-
hour 
glucose level of 140-
199 mg/dL 
DSM IV 
Schizophrenia on 
antipsychotic 
medication 
. . . 31/256 47/256 
Rezaei 200942 General Adult Dec 2007 - May 
2008 
Iran 8 48.7 DM: Fasting blood 
glucose level of > 126 
mg/dl, or random BM 
> 200 mg/dl or 
pharmacological 
therapy for diabetes.            
IFG:FBG ≥ 110 
mg/dl; Excluding 
those with DM. 
DSM IV 
Schizophrenia  
36/372 . . 159/372 . 
Shinozaki 201243 General Adult 2005 - 2007 USA 4 NR DM:Documentation 
in the past medical 
history, current use of 
Females with major 
depressive epsiode 
11/185 . . . . 
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medication for DM, 
and/or documented 
glucose level that met 
criteria for the 
diagnosis of DM. 
Siegler 199544 General Adult 1988 - 1990 USA 2 NR NR Any inpatient with 
hypernatremia: 
Controls with non 
hypernatremia 
combined for 
overall prevalence  
22/256 . . . . 
Yasui-Furukori 
200945 
General Adult Apr 2005 - Mar 
2006 
Japan 2 NR NR DSM IV 
Schizophrenia 
7/130 . . . . 
Zhang 201146 General Adult NR China 4 NR DM: Persistent FPG 
>126mg/dL or 2 hour 
OGTT > 200mg/dL 
DSM IV 
Schizophrenia on 
clozapine 
46/206 . . . . 
Jarvis 200747 Addictions NR USA 3 34.8 IFG: FPG ≥ 100 
mg/dL (range, 102-
110 mg/dL) 
Newly abstinent 
from alcohol men 
and women in a 
residential drug 
treatment facility 
. . . 6/46 . 
Matoo 201148 Addictions Jul 2009 - Dec 
2009 
India 7 37.43 NR Men with ICD 10 
alcohol or opioid 
dependence 
5/110 . . . . 
Nakamura 200449 Addictions Jun 2003 - May 
2004 
Japan 5 NR DM: FPG of 7.0 
mmol/l (126 mg/dl) 
or higher on two or 
ICD 10 alcohol 
dependence  
109/652 . . 203/652 . 
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more occasions when 
examined on separate 
days                            
IFG: FPG ≥ 6.1 and  
< 7.0 mmol/l). 
Haw 201150 Forensic Feb 2010 - Feb 
2010 
UK 2 33 NR Any forensic  
rehabilitation 
inpatient  
. . 20/234 . . 
Kelbrick 201251 Forensic Aug 2009 - Sep 
2009 
UK 2 NR NR Any forensic 
rehabilitation 
inpatient 
33/348 2/348 31/348 . . 
Macfarlane 200452 Forensic Sep 2001 - Sep 
2001 
UK 8 NR NR Any forensic 
inpatient 
. . 35/408 . . 
Vasudev 201253 Forensic Jan 2007 - Jan 
2007 
UK 1 34.5 NR Any male medium 
secure forensic 
psychiatric 
rehabilitation unit 
patient 
. . 2/15 . . 
Cohen 200654 Rehabilitation NR Netherlands 6 NR T2DM: Random BM 
>11.1 
DSM IV 
schizophrenia or 
schizoaffective 
disorder 
    24/266      
O’Brien 200755 Rehabilitation NR Ireland 1 NR NR Any patient on long 
stay ward 
3/27 1/27 2/27 . . 
Udo 201156 Rehabilitation NR Ireland 1 NR NR Any inpatient on 
rehabilitation ward 
4/30 . . . . 
Wang 200657 Rehabilitation Feb 2004 - Jun 
2004 
China 4 49.6 T2DM: Symptoms of 
diabetes, or a random 
fasting blood glucose 
level was higher than 
7.1 mmol/L, or 2-
hour blood 
DSM IV 
schizophrenia on 
antipsychotic 
medication 
. . 42/308 . 75/308 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
 
 33 
glucose level after 
breakfast was higher 
than 11.1 mmol/      
IGT:  6.1 mmol/L    < 
FBG < 7.0 mmmol/L; 
(b) 7.8 
mmol/L < 2-hour 
blood glucose after 
breakfast < 11.1 
mmol/L 
 
 
 
 
 
 
Table two: 
 
The prevalence of diabetes mellitus and impaired glucose metabolism in the adult inpatient psychiatric setting. 
 
  
Unspecified DM T1DM T2DM IFG IGT 
Number of 
cohorts (n) 
Prevalence  % 
(95%CI) 
I2 
(%) 
Number of 
cohorts (n) 
Prevalence % 
(95%CI) 
I2 
(%) 
Number of 
cohorts (n) 
Prevalence  
% (95%CI) 
I2 
(%) 
Number of 
cohorts (n) 
Prevalence  % 
(95%CI) 
I2 
(%) 
Number of 
cohorts (n) 
Prevalence  % 
(95%CI) 
I2 
(%) 
All 31 10 (9-12) 95 5 1 (0-1) 0 13 9 (6-13) 93.4 7 18 (8-28) 97.5 3 22 (16-28)  55.2 
Setting 
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IP General Adult Setting 26 10 (9-12) 95.7 3 1 (0-1) 0 6 9 (4-14) 95.1 5 17 (6-27) 97.5 2 24 (5-42) 47.5 
IP Addictions Setting 2 11 (0-23) 95.9 0 . . 0 . . 2 23 (5-40) 91.5 0 . . 
IP Forensic Setting 1 10 (6-13) . 1 1 (0-1) . 4 9 (7-11) 0 0 . . 0 . . 
IP Rehabilitation Setting 2 12 (4-21) 0 1 4 (0-11) . 3 11 (7-15) 44.1 0 . . 1 25 (20-29) . 
Year of data collection 
<1997 2 9 (7-12) 0 0 . . 1 9 (6-11) . 0 . . 0 . . 
1997-1999 3 8 (7-10) 94.8 0 . . 1 7 (5-10) . 0 . . 0 . . 
2000-2002 3 11 (10-13) 95.2 0 . . 0 . . 0 . . 0 . . 
2003-2005 7 13 (11-14) 87.5 0 . . 1 
14 (10-
18) . 2 21 (2-40) 98.8 1 24 (20-29) . 
2006-2008 4 6 (3-9) 72.5 0 . . 3 10 (0-24) 93.1 1 43 (38-48) . 0 . . 
2009-2011 4 9 (6-13) 74.6 2 1 (0-1) 0 3 9 (7-11) 93.1 1 3 (0-7) . 0 . . 
2012-2014 2 12 (2-23) 90.2 1 1 (0-1) . 1 7 (5-10) . 0 . . 0 . . 
Continent 
Europe 8 9 (7-12) 72.2 5 1 (0-1) 0 8 9 (7-11) 15 3 10 (4-16) 89.1 1 40 (10-70) . 
North America 16 11 (9-12) 97 0 . . 1 7 (5-10) . 1 13 (3-23) . 0 . . 
Asia 7 11 (6-16) 91.8 0 . . 4 10 (2-17) 96.8 3 29 (12-45) 97.9 2 21(16-27) 67 
Diagnostic Category 
Any inpatient 18 11 (10-12) 96.5 4 1 (0-1) 0 8 9 (7-10) 24.2 2 12 (10-14) 0 0 . . 
Schizophrenia/Schizoaffective 
Disorder 4 11 (5-17) 88.2 0 . . 4 9 (11-18) 96.5 2 27 (0-57) 98.9 2 21 (16-27) 67 
Any Mood Disorder 7 8 (4-12) 89.9 1 2 (0-4) . 1 10 (3-17) . 1 3 (0-7) . 1 40 (10-70) . 
Any Substance Dependence 
Disorder 2 11 (0-23) 95.9 0 . . 0 . . 2 23 (5-40) 91.5 0 . . 
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Study Quality 
Low Quality 11 9 (6-11) 84.1 3 1 (0-1) 0 6 10 (8-13) 25.7 2 7 (0-17) 72.4 1 40 (10-70) . 
Medium Quality 8 12 (8-16) 89.4 2 1 (0-1) 0 5 10 (7-13) 73.9 3 19 (7-32) 96.7 2 21 (16-27) 67 
High Quality 12 11 (9-12) 97.7 0 . . 2 4 (0-12) 96.8 2 27 (3-58) 99.2 . . . 
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Online Supplementary Material 
 
eFigure 1: Search terms 
[(diabet* OR glucose) AND (inpatient* OR ward OR residential) AND (psychiatr* OR SMI OR mental* OR 
schizo*)] 
 
eFigure 2: Adapted Newcastle Ottawa Scale Quality Assessment Scale for Cross Sectional Studies 
 
Selection: 
 
1) Representativeness of the sample: 
a) Truly representative of the average in the target population. (Randomised/consecutive)  
b) Somewhat representative of the average in the target population. (non-random sampling) 
c) Selected group of users. 
d) No description of the sampling strategy. 
 
(One point for A or B; Zero points for C or D) 
 
2) Sample size: 
a) Justified and satisfactory. (100)  
b) Not justified. 
 
(One point for A; Zero points for B) 
 
3) Non-respondents: 
a) Comparability between respondents and non-respondents characteristics is established, and the response rate 
is satisfactory. (Participation rate reported) 
b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is 
unsatisfactory. (Participation < 75%) 
c) No description of the response rate or the characteristics of the responders and the non-responders. 
 
(One point for A; Zero points for B or C) 
 
4) Ascertainment of the diagnosis of diabetes/impaired glucose metabolism: 
a) Validated measurement tool. A diagnosis based on international criteria (e.g., the American Diabetes 
Association criteria or World Health Organization criteria. 
b) Non-validated measurement tool, Proxy measurement such as anti-diabetic medication.  
c) No description of the measurement tool. 
 
(Two points for A; One point for B; Zero points for C) 
  
Comparability: 
 
1) The subjects are comparable across studies based on age and gender, based on the study design or analysis.  
a) Comparable 
b) Non-Comparable 
 
(Two points for A; Zero points for B) 
 
Outcome: 
 
1) Assessment of the outcome: 
a) Independent assessment. 
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b) Documented diagnosis. 
c) Self report. 
d) No description. 
 
(Two points for A or B; One point for C; Zero points for D) 
 
2) Statistical test: 
a) The statistical test used to analyze the data is clearly described and appropriate, and the measurement of the 
association is presented, including confidence intervals and the probability level (p value). 
b) The statistical test is not appropriate, not described or incomplete. 
 
(One point for A; Zero points for B) 
 
 
eFigure 3: Included studies flow diagram 
 
 
 
 
 
 
Records screened in 1st sift, n = 
1114 
Records screened in 2nd sift, n = 
N/A 
Records excluded in 1st sift, n = 
1014 
Records excluded in 2nd sift, n = 
N/A 
Studies included in review, n = 
32 study reports representing 
38 unique cohorts 
 
Studies excluded from review, n = 
68 
Reasons for exclusion: (see 
exclusion lists in online 
supplementary material) 
Records identified through 
database searching, n = 1107 
Additional records identified 
through other sources, n = 7  
Full-text articles assessed for 
eligibility, n = 100 
36 st dy reports 
representing 42 unique 
cohorts 
64 
 
Common reasons for 
exclusion: 
n= 32 Non protocol 
population 
n= 7 Article not in English 
n=  14 Prevalence not able to 
be extracted for IP cohort  
n= 11 Other 
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eTable 1: Excluded Studies 
 
Fan, Xiaoduo, Liu, Emily, Pristach, Cynthia, Goff, Donald C., 
Henderson, David C.Higher fasting serum insulin levels are 
associated with a better psychopathology profile in acutely ill non-
diabetic inpatients with schizophrenia. Schizophrenia Research, Sep 
2006, vol. 86, no. 1-3, p. 30-35, 0920-9964 (Sep 2006) 
Preselected population with 
normal blood glucose a priori 
Grover S., Nebhinani N., Chakrabarti S., Avasthi A., Kulhara P., Basu 
D., Mattoo S.K., Malhotra S.Comparative study of prevalence of 
metabolic syndrome in bipolar disorder and schizophrenia from North 
India. Nordic Journal of Psychiatry, January 2014, vol./is. 68/1(72-
77), 0803-9488;1502-4725 (January 2014) 
No individual number of DM 
or IFG or IGT reported 
Massey E.W., Massey J.M. Peroneal palsy in depressed patients. 
Psychosomatics, 1987, vol./is. 28/2(93-94), 0033-3182 (1987) 
Prevalence in inpatients 
receiving neurological 
consultations 
Nguyen, Dang, Brakoulias, Vlasios, Boyce, Philip. An evaluation of 
monitoring practices in patients on second generation antipsychotics. 
Australasian Psychiatry, Aug 2009, vol. 17, no. 4, p. 295-299, 1039-
8562 (Aug 2009) 
No individual number of DM 
or IFG or IGT reported 
Shiloah, Eli, Witz, Shula, Abramovitch, Yehuda, Cohen, Ohad, 
Buchs, Andreas, Ramot, Yoram, Weiss, Mordechai, Unger, 
Abraham, Rapoport, Micha J Effect of acute psychotic stress in 
nondiabetic subjects on beta-cell function and insulin sensitivity. 
Diabetes care, May 2003, vol. 26, no. 5, p. 1462-1467, 0149-5992 
(May 2003) 
Population excludes 
abnormal serum glucose level 
a priori 
Lindenmayer, Jean Pierre, Tedeschi, Frank, Yusim, Anna, Khan, 
Anzalee, Kaushik, Saurabh, Smith, Robert C, Parakadavil, Mohan 
Ziprasidone's effect on metabolic markers in patients with diabetes 
and chronic schizophrenia. Clinical schizophrenia & related 
psychoses, Jan 2012, vol. 5, no. 4, p. 185-192, 1935-1232 (January 
2012) 
Preselected population 
patients with patients with DM 
Chiu C-C. Chen C.-H., Chen B.-Y., Yu S.-H., Lu M.-L. The time-
dependent change of insulin secretion in schizophrenic patients 
treated with olanzapine. Progress in Neuro-Psychopharmacology 
and Biological Psychiatry, August 2010, vol./is. 34/6(866-870), 0278-
5846 (August 2010) 
Preselected population with 
normal blood glucose a priori  
Citrome, Leslie, Jaffe, Ari, Levine, Jerome, Allingham, Baerbel, 
Robinson, James. Relationship between antipsychotic medication 
treatment and new cases of diabetes among psychiatric inpatients. 
Psychiatric services (Washington, D.C.), Sep 2004, vol. 55, no. 9, p. 
1006-1013, 1075-2730 (September 2004) 
Double counting with Citrome 
2006; Collected data 2000-
2002 
Ladea M., Barbu C.M., Rosu D.P.Metabolic imbalance in affective 
disorders Journal of medicine and life, March 2013, vol./is. 6/1(45-
49), 1844-3117 (15 Mar 2013) 
Preselected population 
patients with patients with DM 
Manu, Peter, Correll, Christoph U, Wampers, Martien, van Winkel, 
Ruud, Yu, Weiping, Shiffeldrim, Daphna, Kane, John M, De Hert, 
Marc Insulin secretion in patients receiving clozapine, olanzapine, 
quetiapine and risperidone. Schizophrenia research, Feb 2013, vol. 
143, no. 2-3, p. 358-362 (February 2013) 
Data already included; 
Double counting with Manu 
2012/13 
Mookhoek E.J., Van De Kerkhof P.C.M., Hovens J.E.J.M., Brouwers 
J.R.B.J., Loonen A.J.M. Skin disorders in chronic psychiatric illness. 
Journal of the European Academy of Dermatology and Venereology, 
October 2010, vol./is. 24/10(1151-1156), 0926-9959;1468-3083 
(October 2010) 
Prevalence in inpatients 
seeking dermatological 
consultations; Collection data 
of data NR potential overlap 
with included cohort 
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Mookhoek 2011.  
Basu, Anirban, Meltzer, Herbert Y. Differential trends in prevalence of 
diabetes and unrelated general medical illness for schizophrenia 
patients before and after the atypical antipsychotic era. 
Schizophrenia Research, Sep 2006, vol. 86, no. 1-3, p. 99-109, 
0920-9964 (Sep 2006) 
Not psychiatric IP setting; 
Schizophrenia in all hospitals 
including general hospitals 
Chen Q., Cai Z.-j., Mao P.-x., Zhai Y.-M., Mitchell P.B., Tang Y.-l. 
Effects of risperidone on glucose metabolism in Chinese patients 
with schizophrenia: A prospective study. Journal of Psychiatric 
Research, December 2008, vol./is. 43/2(124-128), 0022-3956 
(December 2008) 
No individual number of DM 
or IFG or IGT reported 
Hansen, Otto. Blood uridine diphosphate glucose in mental disease. 
The British Journal of Psychiatry, Jan 1969, vol. 115, no. 522, p. 557-
562, 0007-1250 (1969) 
Unable to calculate number of 
people with IGT; Uses non 
OGTT method to derive IGT 
Regenold W.T., Thapar R.K., Marano C., Gavirneni S., 
Kondapavuluru P.V. Increased prevalence of type 2 diabetes mellitus 
among psychiatric inpatients with bipolar I affective and 
schizoaffective disorders independent of psychotropic drug use. 
Journal of Affective Disorders, 2002, vol./is. 70/1(19-26), 0165-0327 
(2002) 
Older Adult population 
Rittmannsberger, Hans, Fellinger, Johannes, Foff, Christian, Walli, 
Gertraud, Zaunmüller, Thomas Deterioration of metabolic parameters 
during short-term psychiatric inpatient treatment: a prospective 
naturalistic study. International journal of psychiatry in clinical 
practice, Mar 2012, vol. 16, no. 1, p. 8-17 (March 2012) 
No individual number of DM 
or IFG or IGT reported 
Munshi T., Patel A., Mazhar M.N., Hassan T., Siddiqui 
E.U.Frequency of metabolic syndrome in psychiatric patients, is this 
the time to develop a standardized protocol to reduce the morbidity 
from an acute care psychiatry unit. Journal of the Pakistan Medical 
Association, 2015, vol./is. 65/1(54-58), 0030-9982 (2015) 
11/50 FBG>100 mg/dl of Non 
Met-S cant calculate for 
whole sample 
Reist C., Mintz J., Albers L.J., Jamal M.M., Szabo S., Ozdemir V. 
Second-generation antipsychotic exposure and metabolic-related 
disorders in patients with schizophrenia: An observational 
pharmacoepidemiology study from 1988 to 2002. Journal of Clinical 
Psychopharmacology, February 2007, vol./is. 27/1(46-51), 0271-
0749 (February 2007) 
No individual number of DM 
or IFG or IGT reported 
Ojala K., Niskanen L., Tiihonen J., Paavola P., Putkonen A., Repo-
Tiihonen E. Characterization of metabolic syndrome among forensic 
psychiatric inpatients. Journal of Forensic Psychiatry and 
Psychology, March 2008, vol./is. 19/1(33-51), 1478-9949;1478-9957 
(March 2008) 
No individual number of DM 
or IFG or IGT reported 
Lindenmayer J.-P., Khan A., Wance D., Maccabee N., Kaushik S. 
Outcome evaluation of a structured educational wellness program in 
patients with severe mental illness. Journal of Clinical Psychiatry, 
October 2009, vol./is. 70/10(1385-1396), 0160-6689 (October 2009) 
T2DM/IFG or IGT reported 
combined at baseline unable 
to calculate prevalence of 
each 
 
Lyness J.M., Caine E.D., Cox C., King D.A., Conwell Y., Olivares T. 
Cerebrovascular risk factors and later-life major depression: Testing 
a small-vessel brain disease model. American Journal of Geriatric 
Psychiatry, December 1998, vol./is. 6/1(5-13), 1064-7481  
Older Adult inpatients 
Zeugmann S., Quante A., Heuser I., Schwarzer R., Anghelescu I. 
Inflammatory biomarkers in 70 depressed inpatients with and without 
the metabolic syndrome Journal of Clinical Psychiatry, August 2010, 
vol./is. 71/8(1007-1016), 0160-6689 (August 2010) 
No individual number of DM 
or IFG or IGT reported 
Susce, Margaret T, Villanueva, Noemi, Diaz, Francisco J, de Leon, 
Jose  Obesity and associated complications in patients with severe 
mental illnesses: a cross-sectional survey. The Journal of clinical 
psychiatry, Feb 2005, vol. 66, no. 2, p. 167-173, 0160-6689 
(February 2005) 
Mixed IP and OP; NR 
separately 
Carney, Caroline P, Jones, Laura, Woolson, Robert F .Medical Mixed IP and OP; NR 
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comorbidity in women and men with schizophrenia: a population-
based controlled study. Journal of general internal medicine, Nov 
2006, vol. 21, no. 11, p. 1133-1137 (November 2006) 
separately  
Cohen D., Puite B., Dekker J., De Wied C.G.Diabetes Mellitus in 93 
chronic schizophrenic inpatients European Journal of Psychiatry, 
January 2003, vol./is. 17/1(38-47), 0213-6163 (January/March 2003) 
Article in Spanish 
Rothbard A.B., Blank M.B., Staab J.P., Tenhave T., Young D.S., 
Berry S.D., Eachus A.A.S. Previously undetected metabolic 
syndromes and infectious diseases among psychiatric inpatients. 
Psychiatric Services, April 2009, vol./is. 60/4(534-537), 1075-
2730;1557-9700 (April 2009) 
Unable to calculate accurate 
n for diabetes. Differing 
measures reported.  
Krakowski M., Czobor P., Citrome L. Weight gain, metabolic 
parameters, and the impact of race in aggressive inpatients 
randomized to double-blind clozapine, olanzapine or haloperidol. 
Schizophrenia Research, May 2009, vol./is. 110/1-3(95-102), 0920-
9964 (May 2009) 
No individual number of DM 
or IFG or IGT reported only 
serum glucose levels given 
Chien I.-C., Hsu J.-H., Lin C.-H., Bih S.-H., Chou Y.-J., Chou P. 
Prevalence of diabetes in patients with schizophrenia in Taiwan: A 
population-based National Health Insurance study. Schizophrenia 
Research, June 2009, vol./is. 111/1-3(17-22), 0920-9964 (June 
2009) 
Mixed OP and IP. IP data not 
reported separately 
Lin C.-C., Bai Y.-M., Wang Y.-C., Chen T.-T., Lai I.-C., Chen J.-Y., 
Chen S.-Y., Gau S.S.F., Liou Y.-J. Improved body weight and 
metabolic outcomes in overweight or obese psychiatric patients 
switched to amisulpride from other atypical antipsychotics. Journal of 
Clinical Psychopharmacology, December 2009, vol./is. 29/6(529-
536), 0271-0749 (December 2009)  
No individual number of DM 
or IFG or IGT reported only 
serum glucose level given 
De Hert M, van Winkel R, Van Eyck D et al. Prevalence of the 
metabolic syndrome in patients with schizophrenia treated with 
antipsychotic medication. Schizophr Res 2006; 83: 87-93. 
Mixed OP and IP data. IP 
date not reported separately 
van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes 
and the metabolic syndrome in a sample of patients with bipolar 
disorder. Bipolar Disord. 2008;10(2):342–348. 
Mixed OP and IP data. IP 
date not reported separately 
Meyer J.M., Pandina G., Bossie C.A., Turkoz I., Greenspan A.Effects 
of switching from olanzapine to risperidone on the prevalence of the 
metabolic syndrome in overweight or obese patients with 
schizophrenia or schizoaffective disorder: Analysis of a multicenter, 
rater-blinded, open-label study. Clinical Therapeutics, December 
2005, vol./is. 27/12(1930-1941), 0149-2918;1879-114X (December 
2005) 
Mixed OP and IP data. IP 
date not reported separately  
Teixeira P.J.R., Rocha F.L.The prevalence of metabolic syndrome 
among psychiatric inpatients in Brazil. Revista de Psiquiatria do Rio 
Grande do Sul, December 2007, vol./is. 29/4(330-336), 0101-8108 
(December 2007) 
No individual number of DM 
or IFG or IGT reported 
Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji 
Z., Koch G., Hamer R.M. Atypical and conventional antipsychotic 
drugs in treatment-naive first-episode schizophrenia: a 52-week 
randomized trial of clozapine vs chlorpromazine. 
Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology, May 2003, vol./is. 28/5(995-
1003), 0893-133X (May 2003) 
No individual number of DM 
or IFG or IGT reported only 
serum glucose level given 
Gupta S., Steinmeyer C., Frank B., Madhusoodanan S., Lockwood 
K., Lentz B., Keller P. Hyperglycemia and hypertriglyceridemia in real 
world patients on antipsychotic therapy. American journal of 
therapeutics, September 2003, vol./is. 10/5(348-355), 1075-2765 
(2003 Sep-Oct) 
Mixed OP and IP data. IP 
date not reported separately 
Lu M.L., Lane H.Y., Lin S.K., Chen K.P., Chang W.H. Adjunctive 
fluvoxamine inhibits clozapine-related weight gain and metabolic 
disturbances. The Journal of clinical psychiatry, June 2004, vol./is. 
65/6(766-771), 0160-6689 (Jun 2004) 
No individual number of DM 
or IFG or IGT reported only 
serum glucose level given 
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Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., Siu C.O.. 
Randomized, controlled, double-blind multicenter comparison, of the 
efficacy and tolerability of ziprasidone and olanzapine in acutely III 
inpatients with schizophrenia or schizoaffective disorder. American 
Journal of Psychiatry, October 2004, vol./is. 161/10(1837-1847), 
0002-953X (October 2004) 
No individual number of DM 
or IFG or IGT reported only 
serum glucose level given 
Straker D., Correll C.U., Kramer-Ginsberg E., Abdulhamid N., Koshy 
F., Rubens E., Saint-Vil R., Kane J.M., Manu P.. Cost-effective 
screening for the metabolic syndrome in patients treated with 
second-generation antipsychotic medications. American Journal of 
Psychiatry, June 2005, vol./is. 162/6(1217-1221), 0002-953X (June 
2005) 
No calculable n for DM or IFG 
only glucose level given, only 
calculable for MS population 
not total. 
De Leon J., Susce M.T., Diaz F.J., Rendon D.M., Velasquez D.M. 
Variables associated with alcohol, drug, and daily smoking cessation 
in patients with severe mental illnesses. Journal of Clinical 
Psychiatry, November 2005, vol./is. 66/11(1447-1455), 0160-6689 
(November 2005) 
Mixed OP and IP data. IP 
date not reported separately 
Desai M.M., Rosenheck R.A., Druss B.G., Perlin J.B. Mental 
disorders and quality of diabetes care in the veterans health 
administration. American Journal of Psychiatry, September 2002, 
vol./is. 159/9(1584-1590), 0002-953X (September 2002) 
Not psychiatric IP sample.  
Goethe J.W., Szarek B.L., Caley C.F. Metabolic syndrome in 
psychiatric inpatients treated for depression. Metabolic Effects of 
Psychotropic Drugs, 2009, vol./is. 26/(90-104), 1662-2685;1662-4505 
(2009) 
Reports individual number for 
criteria of MetS FBG >110 or 
diagnosis of DM combined   
Greco, Maria Isabella, Gallotti, Paolo Maria, Magnolfi, Valeria, 
Alberti, Giorgio Gabriele Esiste un'associazione tra patologie 
psichiatriche e diabete mellito? Risultati di uno studio su una 
popolazione psichiatrica ospedaliera.. Psichiatria e Psicoterapia, Dec 
2006, vol. 25, no. 4, p. 346-353, 1724-4919 (Dec 2006) 
Article in Italian 
Usta, Evrim, Metin, Özen, Birsöz, Sunar Şizofreni ve diyabet: Yeni 
kuşak antipsikotiklerin yol açtiği diyabet veya metabolik sendrom. 
Klinik Psikofarmakoloji Bülteni / Bulletin of Clinical 
Psychopharmacology, Dec 2007, vol. 17, no. 4, p. 207-216, 1017-
7833 (Dec 2007) 
Article in Turkish 
Leonard, Hasse, Hoheneck, Dagmar. Metabolic side effects of the 
atypical antipsychotic olanzapine in an inpatient population of adults 
with developmental disabilities. Mental Health Aspects of 
Developmental Disabilities, Jan 2006, vol. 9, no. 1, p. 18-22, 1057-
3291 (Jan-Mar 2006) 
No individual number of DM 
or IFG or IGT reported 
Kelly, Deanna L., Kreyenbuhl, Julie, Love, Raymond C., Van-Duong, 
Quynh, Conley, Robert R.Six-Month Review of Weight and Metabolic 
Parameters in Patients Receiving Clozapine, Risperidone, 
Olanzapine, or Quetiapine. Journal of Clinical Psychiatry, Sep 2003, 
vol. 64, no. 9, p. 1133-1134, 0160-6689 (Sep 2003) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels.  
Campbell, E Cabrina, DeJesus, Melissa, Herman, Barry K, Cuffel, 
Brian J, Sanders, Kafi N, Dodge, William, Dhopesh, Vasant, Caroff, 
Stanley N A pilot study of antipsychotic prescribing decisions for 
acutely-Ill hospitalized patients. Progress in neuro-
psychopharmacology& biological psychiatry, Jan 2011, vol. 35, no. 1, 
p. 246-251 (January 15, 2011) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Suzuki, Yutaro, Sugai, Takuro, Fukui, Naoki, Watanabe, Junzo, Ono, 
Shin, Tsuneyama, Nobuto, Saito, Mami, Someya, Toshiyuki Low 
prevalence of metabolic syndrome and its prediction in Japanese 
inpatients with schizophrenia. Human Psychopharmacology: Clinical 
and Experimental, Mar 2013, vol. 28, no. 2, p. 188-191, 0885-6222 
(Mar 2013) 
FBG >100 mg/dl prevalence 
reported. Nil distinction 
between IFG and DM. Nil 
indiviusal number reported.  
Deuschle, M., Paul, F., Brosz, M., Bergemann, N., Franz, M., 
Kammerer-Ciernioch, J., Lautenschlager, M., Lederbogen, F., 
Roesch-Ely, D., Weisbrod, M., Kahl, K. G., Reichmann, J., Gross, J., 
IP and OP cohort; Not 
reported separately 
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Umbreit, J.Assessment of cardiovascular disease risk in patients with 
schizophrenia spectrum disorders in German psychiatric hospitals: 
Results of the pharmacoepidemiologic CATS study. Social 
Psychiatry and Psychiatric Epidemiology, Aug 2013, vol. 48, no. 8, p. 
1283-1288, 0933-7954 (Aug 2013) 
Schimmelbusch, Werner H., Mueller, Peter S., Sheps, Jack The 
positive correlation between insulin resistance and duration of 
hospitalization in untreated schizophrenia. The British Journal of 
Psychiatry, Apr 1971, vol. 118, no. 545, p. 429-436, 0007-1250 (Apr 
1971) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Marsay, C., Szabo, C. P. Screening for metabolic syndrome-
adherence to guidelines. African Journal of Psychiatry, Mar 2011, 
vol. 14, no. 1, p. 64-66, 1994-8220 (Mar 2011) 
OP cohort 
Wehring, Heidi J., Liu, Fang, McMahon, Robert P., Mackowick, 
Kristen M., Love, Raymond C., Dixon, Lisa, Kelly, Deanna L.Clinical 
characteristics of heavy and non-heavy smokers with schizophrenia. 
Schizophrenia Research, Jul 2012, vol. 138, no. 2-3, p. 285-289, 
0920-9964 (Jul 2012) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Caemmerer, Jacqueline, Correll, Christoph U., Maayan, Lawrence 
Acute and maintenance effects of non-pharmacologic interventions 
for antipsychotic associated weight gain and metabolic abnormalities: 
A meta-analytic comparison of randomized controlled trials. 
Schizophrenia Research, Sep 2012, vol. 140, no. 1-3, p. 159-168, 
0920-9964 (Sep 2012) 
Meta-analysis with 3 IP trials. 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Mitchell, Alex J., Vancampfort, Davy, Sweers, Kim, van Winkel, 
Ruud, Yu, Weiping, De Hert, Marc Prevalence of metabolic 
syndrome and metabolic abnormalities in schizophrenia and related 
disorders—A systematic review and meta-analysis. Schizophrenia 
Bulletin, Mar 2013, vol. 39, no. 2, p. 306-318, 0586-7614 (Mar 2013) 
MA for MetS prevalence. 
Cross-checked for 
references. 
Hjorth P., Davidsen A.S., Kilian R., Pilgaard Eriksen S., Jensen S.O., 
Sorensen H.O., Munk-Jorgensen P.Improving the physical health of 
long-term psychiatric inpatients Australian and New Zealand Journal 
of Psychiatry, September 2014, vol./is. 48/9(861-870), 0004-
8674;1440-1614 (September 2014) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Wetterling, Tilman, Schneider, Barbara, Weber, Bernhard. Blood 
glucose in chronic schizophrenic patients treated with antipsychotics. 
Psychiatrische Praxis, Mar 2007, vol. 34, no. 2, p. 76-80, 0303-4259 
(March 2007) 
Article in German 
Hallahan, Brian, Lyons, Declan, Doyle, Patrick Bone mineral density 
and general health of long-term residential psychiatric inpatients. 
Irish Journal of Psychological Medicine, Sep 2008, vol. 25, no. 3, p. 
95-99, 0790-9667 (Sep 2008) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Abdullah, Anwar K, Khan, Salman, Mustafa, Shaheen F, Qutubuddin, 
Abu A, Davis, Charles M Vitamin d status and cardiometabolic risk 
factors in long-term psychiatric inpatients. The primary care 
companion for CNS disorders, Jan 2012, vol. 14, no. 1 (2012) 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated.  
The Bermudes, Richard A, Keck, Paul E, Welge, Jeffrey A 
prevalence of the metabolic syndrome in psychiatric inpatients with 
primary psychotic and mood disorders. Psychosomatics, Nov 2006, 
vol. 47, no. 6, p. 491-497, 0033-3182 (2006 Nov-Dec) 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated. 
Boke O., Aker S., Sarisoy G., Saricicek E.B., Sahin A.R.Prevalence 
of metabolic syndrome among inpatients with schizophrenia. 
International Journal of Psychiatry in Medicine, 2008, vol./is. 
38/1(103-112), 0091-2174;1541-3527 (2008) 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated. 
Coakley C., Bolton P., Flaherty L., Kopeski L.M., Slifka K., 
Sutherland M.A. The incidence of metabolic risk factors in an 
inpatient psychiatric setting. Journal of Psychosocial Nursing and 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
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Mental Health Services, March 2012, vol./is. 50/3(24-30), 0279-3695 
(March 2012) 
of DM and IFG numbers able 
to be calculated. 
Gossell-Williams M., Martin J., Neita S., Gibson R.C., Abel W., 
Sewell C., McGrowder D. Prevalence of the metabolic syndrome in 
patients presenting to the university hospital of the West Indies: a 
need to adopt proactive screening and specific management policy 
The West Indian medical journal, November 2012, vol./is. 61/8(802-
808), 0043-3144 (Nov 2012) 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated. 
Lin C.-C., Yu S.-C., Wu B.-J., Chang D.-J. Measurement of waist 
circumference at different sites affects the detection of abdominal 
obesity and metabolic syndrome among psychiatric patients. 
Psychiatry Research, May 2012, vol./is. 197/3(322-326), 0165-
1781;1872-7123 (30 May 2012) 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated. 
Marthoenis M., Aichberger M.C., Puteh I., Syahrial S., Schouler-Ocak 
M.Metabolic syndrome among psychiatric inpatients with 
schizophrenia in Indonesia Asian Journal of Psychiatry, June 2015, 
vol./is. 15/(10-14), 1876-2018;1876-2026 (01 Jun 2015) 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated. 
Kai G. Kahl, Wiebke Greggersen, Ulrich Schweiger et al. Prevalence 
of the metabolic syndrome in men and women with alcohol 
dependence: results from a cross-sectional study during behavioural 
treatment in a controlled environment. Addiction 2010105, 1921–
1927 
Reports number of MetS 
criteria elevated fasting 
glucose or DM; No separation 
of DM and IFG numbers able 
to be calculated. 
Nagamine, Takahiko Hyperlipidemia in psychiatric inpatients. Seishin 
Igaku (Clinical Psychiatry), Nov 2001, vol. 43, no. 11, p. 1263-1268, 
0488-1281 (Nov 2001) 
Article in Japanese 
Suzuki Y., Mikami T., Tajiri M., Kunizuka T., Abe H., Someya 
T.Effects of hospitalization in a psychiatric ward on the body weight 
of Japanese patients with schizophrenia. International Journal of 
Psychiatry in Medicine, January 2013, vol./is. 45/3(261-268), 0091-
2174;1541-3527 (01 Jan 2013) 
No number of DM or IFG or 
IGT reported only serum 
glucose levels. 
Sugai T., Suzuki Y., Fukui N., Watanabe J., Ono S., Tsuneyama N., 
Someya T.Excessive insulin secretion in japanese schizophrenic 
patients treated with antipsychotics despite normal fasting glucose 
levels. Journal of Clinical Psychopharmacology, December 2012, 
vol./is. 32/6(750-755), 0271-0749;1533-712X (December 2012) 
Reports serum glucose 
conentration following OGTT. 
Nil number of individuals with 
IGT reported.  
Shafer, Alan B, Ray, Ryan Kumar, Becker, Emilie A General medical 
care external hospitalizations for patients in Texas state mental 
health hospitals. Texas medicine, Mar 2013, vol. 109, no. 3, p. e1. 
(March 2013) 
No DM prevalence in 
inpatient psychiatric cohort 
reported. 
Konarzewska, Beata, Waszkiewicz, Napoleon, Galińska, Beata, 
Szulc, Agata. Fasting insulin serum levels and psychopathology 
profiles in male schizophrenic inpatients treated with olanzapine or 
risperidone. Neuro endocrinology letters, Jan 2013, vol. 34, no. 4, p. 
322-328, 0172-780X (2013) 
Excludes DM patients a priori. 
No DM or IFG/IGT number 
reported only serum glucose 
levels.   
Bahtiyar, Gül, Weiss, Karolina, Sacerdote, Alan S Novel endocrine 
disrupter effects of classic and atypical antipsychotic agents and 
divalproex: induction of adrenal hyperandrogenism, reversible with 
metformin or rosiglitazone. Endocrine practice : official journal of the 
American College of Endocrinology and the American Association of 
Clinical Endocrinologists, Oct 2007, vol. 13, no. 6, p. 601-608 
(October 2007) 
Included patients were those 
patients with known metabolic 
abnormalities referred to an 
endocrine service.  
Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic 
syndrome and the risk of coronary heart disease in 367 patients 
treated with second-generation antipsychotic drugs. J Clin Psychiatry 
2006;67:575–583. 
Unable to calculate number of 
patients with DM  
Chien IC, Wu EL, Lin CH, Chou YJ, Chou P. Prevalence of Prevalence reported for both 
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diabetes in patients with major depressive disorder: a population 
based study. Compr Psychiatry 2012;53(5):569–575. 
in and outpatients, unable to 
extract inpatient data alone. 
Amital D, Fostick L, Silberman A, et al. Physical co-morbidity 
among treatment resistant vs. treatment responsive patients 
with major depressive disorder. Eur Neuropsychopharmacol 
2013;23(8):895–901. 
Prevalence reported for both 
in and outpatients, unable to 
extract inpatient data alone 
Schoepf D, Uppal H, Potluri R, Chandran S, Heun R. Comorbidity 
and its relevance on general hospital based mortality in major 
depressive disorder: a naturalistic 12-year follow-up in general 
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eFigure 4: Forest Plots: 
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b) Prevalence of T1DM 
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c) Prevalence of T2DM 
 
d) Prevalence of IFG 
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eFigure 5: Funnel Plots: 
a) Unspecified DM: Eggers Test: No small-study effects; P = 0.397 
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b) T1DM: Eggers Test: No small-study effects  P = 0.044 
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c) T2DM: Eggers Test: no small-study effects P = 0.200 
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d) IFG: Eggers Test: no small-study effects P = 0.551 
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e) IGT: Eggers Test: No small-study effects P = 0.611 
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-
analysis, or both.  
1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as 
applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; 
study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key 
findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of 
what is already known.  
4 
Objectives  4 Provide an explicit statement of questions being 
addressed with reference to participants, 
interventions, comparisons, outcomes, and study 
design (PICOS).  
5 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can 
be accessed (e.g., Web address), and, if available, 
provide registration information including registration 
number.  
5 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of 
follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
5 
Information 
sources  
7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to 
identify additional studies) in the search and date last 
searched.  
5 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could 
be repeated.  
Online 
supplement 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
5 
Data items  11 List and define all variables for which data were 
sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
5/6 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether 
this was done at the study or outcome level), and how 
this information is to be used in any data synthesis.  
5 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
6 
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Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
6 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect 
the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
5/6 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity 
or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
7 
Study 
characteristics  
18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
Table 1 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 12).  
Table 1 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, 
for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
Table 2 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
Table 2 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
Table 2  
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
7/ Table 
2 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
9 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk 
of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
9 
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research.  
9 
FUNDING   
Funding  27 Describe sources of funding for the systematic review 
and other support (e.g., supply of data); role of funders 
for the systematic review.  
6 
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For more information, visit: www.prisma-statement.org.  
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